Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
All content for Rx for Biotech is the property of Podcast Host Chris Leidli and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
Restoring Breath: Biologic Innovation for the Most Vulenerable Patients
Rx for Biotech
21 minutes 23 seconds
6 days ago
Restoring Breath: Biologic Innovation for the Most Vulenerable Patients
Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
Rx for Biotech
Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
